الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are common conditions in middle-age or older men. LUTS range from mild to severe, and include obstructive symptoms such as hesitancy, incomplete emptying, and weak stream, and irritative symptoms such as frequency, urgency, and nocturia, that can strongly worsen the quality of life (QoL). For several years, surgery has represented the gold standard of care for this condition, allowing the relief of urinary symptoms and the consequent improvement in QoL.
Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE-5-Is) have showed significant improvements in both (LUTS) and (ED) in men affected by one or both conditions, without a significant increase in adverse events.
The study was performed to determine the relative efficacy and safety of PDE5-Is alone or in combination with alpha-1 adrenergic blockers in LUTS due to BPH. Our study was conducted on 60 patients diagnosed with LUTS/BPH and ED presented at Ain shams university hospital.
They were the same age group (50-70 years old) and were complaining of moderate to severe prostatic symptoms, with IPSS > 13, when combining sildenafil 25 mg and tamsulosin 0.4 m, or vardenafil 10 mg and tamsulosin 0.4mg, IPSS score showed greater improvement than using either of the 2 drugs alone. The same result was found in Q-max and IIEF.
The combination of PDE5-Is with alpha-blockers induce statistically significant improvement of maximum flow rate as compared with alpha-blockers alone, in addition to the positive effect on micturition and sexual activity.
Younger men with lower BMI and severe urinary symptoms seem to be the best candidates for PDE5-Is in terms of improvement of their urinary function. Headache, dyspepsia, and back pain are the most frequently reported AEs after PDE5-Is in men with LUTS/BPH.